Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Genscript Biotech Management

Management Kriterienprüfungen 2/4

Genscript Biotech's CEO ist Weihui Shao, ernannt in Jul 2021, hat eine Amtszeit von 2.83 Jahren. besitzt direkt 0.021% der Aktien des Unternehmens, im Wert von HK$4.68M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.5 Jahre bzw. 7.1 Jahre.

Wichtige Informationen

Weihui Shao

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	2.9yrs
Eigentum des Geschäftsführers	0.02%
Durchschnittliche Amtszeit des Managements	3.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	7.2yrs

Jüngste Management Updates

Recent updates

Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch

Jun 05

A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)

May 10

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 13

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Mar 13

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 26

Is Genscript Biotech (HKG:1548) A Risky Investment?

Nov 21

Is Genscript Biotech (HKG:1548) A Risky Investment?

Aug 22

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Apr 04

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Apr 03

Is Genscript Biotech (HKG:1548) A Risky Investment?

Apr 02

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Feb 07

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Dec 14

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 09

Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?

Mar 20

Are Insiders Selling Genscript Biotech Corporation (HKG:1548) Stock?

Feb 13

Did The Underlying Business Drive Genscript Biotech's (HKG:1548) Lovely 753% Share Price Gain?

Jan 09

Could The Genscript Biotech Corporation (HKG:1548) Ownership Structure Tell Us Something Useful?

Dec 05

Geschäftsführer

Weihui Shao (44 yo)

2.9yrs

Amtszeit

Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jiange Meng	Executive Chairman	8.8yrs	US$1.07m	0.013% $ 2.6m
Weihui Shao	CEO & COO	2.9yrs	keine Daten	0.021% $ 4.1m
Ye Wang	Co-Founder	22.4yrs	US$615.00k	0.037% $ 7.1m
Shiniu Wei	Chief Financial Officer	3.5yrs	keine Daten	keine Daten
Fangliang Zhang	co-founder & Executive Director	1.5yrs	US$271.00k	keine Daten
Li Zhu	Chief Strategy Officer & Executive Director	3.6yrs	US$529.00k	0.058% $ 11.3m
Wai Ling Wong	Company Secretary	8.8yrs	keine Daten	keine Daten

3.5yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrenes Management: 1548Das Führungsteam des Unternehmens gilt als erfahren (3.5 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jiange Meng	Executive Chairman	8.8yrs	US$1.07m	0.013% $ 2.6m
Ye Wang	Co-Founder	9.1yrs	US$615.00k	0.037% $ 7.1m
Fangliang Zhang	co-founder & Executive Director	2.1yrs	US$271.00k	keine Daten
Li Zhu	Chief Strategy Officer & Executive Director	3.6yrs	US$529.00k	0.058% $ 11.3m
George Church	Member of Advisory Board	4.8yrs	keine Daten	keine Daten
Yuexin Pan	Non-Executive Director	8.8yrs	US$64.00k	0.0027% $ 515.4k
Hong Xin Guo	Independent Non-Executive Director	8.8yrs	US$95.00k	0.0029% $ 564.0k
Zumian Dai	Independent Non-Executive Director	8.8yrs	US$105.00k	keine Daten
Xuehai Wang	Independent Non-Executive Director	3.6yrs	US$120.00k	keine Daten
Luquan Wang	Non-Executive Director	9.1yrs	keine Daten	0.030% $ 5.8m
Jiuan Pan	Independent Non-Executive Director	5.6yrs	US$124.00k	keine Daten
Jiafen Wang	Non-Executive Director	5.6yrs	US$51.00k	0.00019% $ 37.0k

7.2yrs

Durchschnittliche Betriebszugehörigkeit

57.5yo

Durchschnittliches Alter

Erfahrener Vorstand: 1548Die Vorstandsmitglieder gelten als erfahren (7.1 Jahre durchschnittliche Amtszeit).

Genscript Biotech Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Executive Chairman recently sold HK$610k worth of stock

Recent updates

Slammed 28% Genscript Biotech Corporation (HKG:1548) Screens Well Here But There Might Be A Catch

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

A Look At The Fair Value Of Genscript Biotech Corporation (HKG:1548)

Full year 2023 earnings: EPS exceeds analyst expectations

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Consensus estimates of losses per share improve by 12%

Consensus EPS estimates upgraded to US$0.054 loss, revenue downgraded

Investors Appear Satisfied With Genscript Biotech Corporation's (HKG:1548) Prospects As Shares Rocket 29%

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

New minor risk - Profitability

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

Genscript Biotech Corporation (HKG:1548) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Executive Chairman recently sold HK$610k worth of stock

Executive Chairman exercised options and sold HK$4.5m worth of stock

Is Genscript Biotech (HKG:1548) A Risky Investment?

Independent Non-Executive Director exercised options and sold HK$1.6m worth of stock

Non-Executive Director exercised options and sold HK$2.4m worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

Is Genscript Biotech (HKG:1548) A Risky Investment?

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Consensus revenue estimates fall by 19%

Time To Worry? Analysts Just Downgraded Their Genscript Biotech Corporation (HKG:1548) Outlook

Analysts Have Been Trimming Their Genscript Biotech Corporation (HKG:1548) Price Target After Its Latest Report

Is Genscript Biotech (HKG:1548) A Risky Investment?

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Genscript Biotech Corporation (HKG:1548) Shares Could Be 25% Below Their Intrinsic Value Estimate

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

What Is Genscript Biotech Corporation's (HKG:1548) Share Price Doing?

Less than half of directors are independent

Genscript Biotech Corporation (HKG:1548) Shares Could Be 22% Below Their Intrinsic Value Estimate

Is Genscript Biotech (HKG:1548) Using Debt Sensibly?

Consensus forecasts updated

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Co-Founder exercised options and sold HK$327k worth of stock

Genscript Biotech Corporation Announces Board Changes

Less than half of directors are independent

Health Check: How Prudently Does Genscript Biotech (HKG:1548) Use Debt?

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Consensus forecasts updated

Key Executive exercised options and sold HK$897k worth of stock

Board Member exercised options and sold HK$1.1m worth of stock

Board Member recently sold HK$2.1m worth of stock

Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Is It Time To Consider Buying Genscript Biotech Corporation (HKG:1548)?

Co-Founder exercised options and sold HK$93m worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Estimating The Fair Value Of Genscript Biotech Corporation (HKG:1548)

Key Executive recently sold HK$9.1m worth of stock

Co-Founder exercised options and sold HK$165m worth of stock

Co-Founder exercised options and sold HK$72m worth of stock

Co-Founder exercised options and sold HK$74m worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test